These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 19149719)
21. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. Niwa R; Satoh M J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555 [TBL] [Abstract][Full Text] [Related]
22. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes]. Siberil S; Dutertre CA; Boix C; Teillaud JL Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389 [TBL] [Abstract][Full Text] [Related]
25. New technologies in therapeutic antibody development. Brekke OH; Løset GÅ Curr Opin Pharmacol; 2003 Oct; 3(5):544-50. PubMed ID: 14559101 [TBL] [Abstract][Full Text] [Related]
26. Antibody Phage Display. Shim H Adv Exp Med Biol; 2017; 1053():21-34. PubMed ID: 29549633 [TBL] [Abstract][Full Text] [Related]
27. Natural and designer binding sites made by phage display technology. Hoogenboom HR; Chames P Immunol Today; 2000 Aug; 21(8):371-8. PubMed ID: 10916139 [TBL] [Abstract][Full Text] [Related]
28. Phage display for the production of human monoclonal antibodies against human pathogens. Mancini N; Carletti S; Perotti M; Canducci F; Mammarella M; Sampaolo M; Burioni R New Microbiol; 2004 Oct; 27(4):315-28. PubMed ID: 15646045 [TBL] [Abstract][Full Text] [Related]
29. Molecular considerations for development of phage antibody libraries. Tohidkia MR; Barar J; Asadi F; Omidi Y J Drug Target; 2012 Apr; 20(3):195-208. PubMed ID: 21950316 [TBL] [Abstract][Full Text] [Related]
30. Guidelines to cell engineering for monoclonal antibody production. Rita Costa A; Elisa Rodrigues M; Henriques M; Azeredo J; Oliveira R Eur J Pharm Biopharm; 2010 Feb; 74(2):127-38. PubMed ID: 19853660 [TBL] [Abstract][Full Text] [Related]
31. Three decades of human monoclonal antibodies: past, present and future developments. Steinitz M Hum Antibodies; 2009; 18(1-2):1-10. PubMed ID: 19478393 [TBL] [Abstract][Full Text] [Related]
32. [Development of platform technology using molecular display]. Shibasaki S Yakugaku Zasshi; 2009 Nov; 129(11):1333-40. PubMed ID: 19881205 [TBL] [Abstract][Full Text] [Related]
33. Expression and refolding technologies for production of recombinant proteins. Arakawa T Curr Pharm Biotechnol; 2010 Apr; 11(3):231-2. PubMed ID: 20406165 [No Abstract] [Full Text] [Related]
34. Therapeutic antibody engineering by high efficiency cell screening. Doerner A; Rhiel L; Zielonka S; Kolmar H FEBS Lett; 2014 Jan; 588(2):278-87. PubMed ID: 24291259 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic antibodies: magic bullets hit the target. Gura T Nature; 2002 Jun; 417(6889):584-6. PubMed ID: 12050630 [No Abstract] [Full Text] [Related]
37. From rodent reagents to human therapeutics using antibody guided selection. Osbourn J; Groves M; Vaughan T Methods; 2005 May; 36(1):61-8. PubMed ID: 15848075 [TBL] [Abstract][Full Text] [Related]
39. Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation. Wurch T; Lowe P; Caussanel V; Bes C; Beck A; Corvaia N Curr Pharm Biotechnol; 2008 Dec; 9(6):502-9. PubMed ID: 19075688 [TBL] [Abstract][Full Text] [Related]